Barbara Klencke - 30 Jun 2025 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Director
Signature
/s/ Zoran Zdraveski, Attorney-in-Fact
Issuer symbol
TCRX
Transactions as of
30 Jun 2025
Transactions value $
$0
Form type
4
Filing time
02 Jul 2025, 16:32:51 UTC
Previous filing
16 Jun 2025
Next filing
19 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klencke Barbara Director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM /s/ Zoran Zdraveski, Attorney-in-Fact 02 Jul 2025 0001647647

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +67K $0.00 67K 30 Jun 2025 Voting Common Stock 67K $1.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney